Helix BioPharma Corp. announced a private placement of 12,766,667 common shares of the company at a price of CAD 0.15 per common share for gross proceeds of CAD 1,915,000.05 on March 28, 2024. The Offering is subject to customary closing conditions including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange.

In connection with the closing, the Company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The Common Shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws.